2015
Overview
Antiphospholipid syndrome (APS) is a disorder of the immune system that can lead to blood clots and other complications. It is also known as Hughes syndrome, after the doctor who first discovered it, and is commonly associated with Hematology and Oncology research. Individuals with APS produce abnormal proteins called antiphospholipid antibodies that mistakenly attack healthy cells in the body. This leads to inflammation and the formation of blood clots, which can cause a variety of symptoms such as stroke, heart attack, deep vein thrombosis, and pulmonary embolism. APS can also lead to pregnancy complications, including recurrent miscarriages, fetal growth restriction, and pre-eclampsia. Diagnosing APS can be challenging as symptoms can be non-specific and vary widely among patients. However, treatment usually involves the use of anticoagulant medication such as heparin or warfarin. In some cases, immunosuppressive therapy may also be recommended. Research in Hematology and Oncology on APS is ongoing, with studies focusing on improving diagnosis, understanding the underlying mechanisms of the disease, and developing new treatments. Additionally, researchers are exploring the relationship between APS and other autoimmune disorders, as well as its association with cancer. Overall, understanding the mechanisms and treatments of APS is important in improving patient outcomes and preventing life-threatening complications.
Research published in this journal
3 peer-reviewed articles, ranked by relevance. Each links to its DOI.
2020
2016
How this research is being cited
The 3 articles above have been cited 4 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
-
Dina Ashraf Abdelhady et al. · 2025 · European Journal of Medical Research
-
2025 · European journal of medical research
-
S. Dubey et al. · 2022 · Rheumatology
-
2022 · Lara D. Veeken
A sample of recent works citing this journal's research on Antiphospholipid Syndrome, linking to each citing work.